Originally isolated from a protein found in human gastric juice, this peptide has attracted significant attention in preclinical research due to its potential roles in supporting tissue repair and cellular integrity
This approach allows clinicians to personalize therapy based on individual metabolic pathways and genetic predispositions, maximizing weight loss and metabolic health outcomes without proportional price increases
It's not like that with GLP-1
Both trials demonstrated twice daily oral doses of nerandomilast (9 mg and 18 mg) significantly reduced the decline in forced vital capacity (FVC) from baseline at week 52, compared to placebo (adjusted mean change from baseline in FVC: FIBRONEER-IPF, -138.6 mL with nerandomilast 9 mg, -114.7 mL with nerandomilast 18 mg, -183.5 mL with placebo
HIMS to Introduce Compounded GLP-1 Injections, What Plan Sponsors Need to Know Scripta May 28, 2024 3 min read Updated: Jun 14, 2024 Hims & Hers' (HIMS) latest move to introduce compounded GLP-1 injections into its weight loss program is stirring up excitement and raising a few eyebrows among plan sponsors
Its weight-management evidence comes largely from the SURMOUNT trial program published in The New England Journal of Medicine in 2022, with SURMOUNT-OSA extending the data to obstructive sleep apnea in 2024
